Podcasts about zuranolone

The FDA has approved the first pill for postpartum depression, Zuranolone (Zurzuvae) on August 4th, 2023. We discuss this and more with Katie Galvin, a former speech language pathologist turned women's functional nutrition practitioner, holistic life coach, and postpartum doula, who shares her personal experience with postpartum health challenges and the flaws in the standard allopathic medical model. She discusses the lack of informed consent and alternative treatment options provided by doctors, the importance of addressing the complexity of postpartum health holistically, and the need for proper nutrition and support during the postpartum period. We examine how the drug Zuranolone became approved, the financial conflicts of interest and the potential harms to mothers that take this drug. The conversation highlights the need for a shift in the medical approach to postpartum care and the recognition of the unique physiological changes and emotional challenges women face during this time. The conversation explores the flaws in the current medical system and the need for a more holistic approach to healthcare. It discusses the pressure on doctors to maintain authority and the consequences of this mindset. The conversation also delves into the pharmaceutical industry's influence on medical practices and the lack of informed consent. The importance of addressing the root causes of health issues and empowering individuals to take control of their own well-being is emphasized. The conversation concludes with a call to resist the current system and seek alternative approaches to healthcare.00:00 Introduction: The Approval of the First Oral Treatment for Postpartum Depression02:26 The Flaws in the Standard Allopathic Medical Model for Postpartum Health11:50 The Lack of Informed Consent and Alternative Treatment Options15:01 The Importance of Nutrition and Support in Postpartum Recovery29:01 The Need for a Shift in the Medical Approach to Postpartum Care31:37 Flaws in the Current Medical System43:17 The Pressure on Doctors and Lack of Informed Consent52:19 Addressing Root Causes and Empowering Individuals55:07 The Influence of the Pharmaceutical Industry56:30 Resisting the Current System and Seeking AlternativesNote: This podcast episode is designed solely for informational and educational purposes, without endorsing or promoting any specific medical treatments. We strongly advise consulting with a qualified healthcare professional before making any medical decisions or taking any actions.*If you are in crisis or believe you have an emergency, please contact your doctor or dial 911. If you are contemplating suicide, call 1-800-273-TALK to speak with a trained and skilled counselor.RADICALLY GENUINE PODCASTDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)—-----------FREE DOWNLOAD! DISTRESS TOLERANCE SKILLS—----------

Episode 171: Postpartum Blues, Depression, and PsychosisFuture Dr. Nguyen defines and explains the difference between baby blues, depression, and psychosis. Dr. Arreaza added comments about screening and management of these conditions. Written by Vy Nguyen, OMSIII, Western University of Health Sciences, College of Osteopathic Medicine of the Pacific. Comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction.Pregnancy is one of the most well-celebrated milestones in one's life. However, once the baby is born, the focus of the family and society quickly shifts to the new member. It is important to continue to care for our mothers and offer them support physically and mentally as they begin their transition into their role. Peripartum mood disorders affect both new and experienced mothers as they navigate through the challenges of motherhood. The challenges of motherhood are not easy to spot, and they include sleep deprivation, physical exhaustion, dealing with pain, social isolation, and financial pressures, among other challenges. Let's focus on 3 aspects of the postpartum period: Postpartum Blues (PPB), Post-partum Depression (PPD) and Post-partum Psychosis (PPP). By the way, we briefly touched on this topic in episode 20, a long time ago. Postpartum blues (PPB) present as transient and self-limiting low mood and mild depressive symptoms that affect more than 50% of women within two or three days of childbirth and resolve within two weeks of onset. Symptoms vary from crying, exhaustion, irritability, anxiety, appetite changes, and decreased sleep or concentration to mood lability. Women are at risk for PPB.Several factors are thought to contribute to the increased risk of postpartum blues including a history of menstrual cycle-related mood changes, mood changes associated with pregnancy, history of major depression, number of lifetime pregnancies, or family history of postpartum depression. Pathogenesis of PPB: While pathogenesis remains unknown, hormonal changes such as a dramatic decrease in estradiol, progesterone, and prolactin have been associated with the development of postpartum blues. In summary, PPB is equivalent to a brief, transient “sad feeling” after the delivery. Peripartum depression (PPD) occurs in 20% of women and is classified as depressive symptoms that appear within six weeks to 1 year after childbirth. Those with baby blues have an increased risk of developing postpartum depression. About 50% of “postpartum” major depressive episodes begin before delivery, thus the term has been updated from “postpartum” to “peripartum” depressive episodes. Some risk factors include adolescent patients, mothers who deliver premature infants, and women living in urban areas. Interestingly, African American and Hispanic mothers are reported to have onset of symptoms within two weeks of delivery instead of six like their Caucasian counterparts. Additional risks include psychological risks such as a personal history of depression, anxiety, premenstrual syndrome, and sexual abuse; obstetric risks such as emergency c-sections and hospitalizations, preterm or low birth infant, and low hemoglobin; social risks such as lack of social support, domestic violence in form of spousal physical/sexual/verbal abuse; lifestyle risks such as smoking, eating sleep patterns and physical activities. Peripartum depression can present with or without psychotic features, which may appear between 1 in 500 or 1 in 1,000 deliveries, more common in primiparous women. Pathogenesis of PPD: Much like postpartum blues, the pathogenesis of postpartum depression is unknown. However, it is known that hormones can interfere with the hypothalamic-pituitary-adrenal axis (HPA) and lactogenic hormones. HPA-releasing hormones increase during pregnancy and remain elevated up to 12 weeks postpartum. The body receptors in postpartum depression are susceptible to the drastic hormonal changes following childbirth which can trigger depressive symptoms. Low levels of oxytocin and prolactin also play a role in postpartum depression causing moms to have trouble with lactation around the onset of symptoms. The USPSTF recommends screening for depression in the adult population, including pregnant and postpartum persons, as well as older adults. Edinburgh Postnatal Depression Scale (EPDS) can be used in postpartum and pregnant persons (Grade B recommendation).Postpartum psychosis (PPP) is a psychiatric emergency that often presents with confusion, paranoia, delusions, disorganized thoughts, and hallucinations. Around 1-2 out of 1,000 new moms experience postpartum psychosis with the onset of symptoms as quickly as several days and as late as six weeks after childbirth. Given the high risk of suicide and harm, individuals with postpartum psychosis require immediate evaluation and treatment. Postpartum psychosis is considered multifactorial, and the single most important risk factor is first pregnancy with family or personal history of bipolar 1 disorder. Other risk factors include a prior history of postpartum psychosis, family history of psychosis, history of schizoaffective disorder or schizophrenia, or discontinuation of psychiatric medications. Studies show that patients with a history of decreased sleep due to manic episodes are twice as likely to have postpartum psychosis at some point in their lives. However, approximately 50% of mothers who experience psychosis for the first time do not have a history of psychiatric disorder or hospitalization. Evaluation.Symptoms of postpartum blues should not meet the criteria for a major depressive episode and should resolve in 2 weeks. The Edinburg Postpartum Depression Scale which is a useful tool for assessing new moms with depressive symptoms. Postpartum depression is diagnosed when the patient presents with at least five depressive symptoms for at least 2 weeks. According to the DSM5, postpartum depression is defined as a major depressive episode with peripartum onset of mood symptoms during pregnancy or in the 4 weeks following delivery. Symptoms for diagnosis include changes in sleep, interest, energy, concentration, appetite, psychomotor retardation or agitation, feeling of guilt or worthlessness, and suicidal ideation or attempt. These symptoms are not associated with a manic or hypomanic episode and can often lead to significant impediments in daily activities. Peripartum-onset mood episodes can present with or without psychotic features. The depression can be so severe that the mother commits infanticide. Infanticide can happen, for example, with command hallucinations or delusions that the infant is possessed.While there are no standard screening criteria in place of postpartum psychosis, questionnaires mentioned earlier such as the Edinburg Postpartum Depression Scale can assess a patient's mood and identify signs of depression and mania. It is important after a thorough history and physical examination to order labs to rule out other medical conditions that can cause depressive and psychotic symptoms. Disorders like electrolyte imbalance, hepatic encephalopathy, thyroid storm, uremia, substance use, infections, and even stroke can mimic a psychiatric disorder. So, How can we treat patients who are diagnosed with a peripartum mood disorder?Management.On the spectrum of peripartum mood disorders, postpartum blues are the least severe and should be self-limiting by week 2. However, patients should be screened for suicidal ideation, paranoia, and homicidal ideation towards the newborn. Physicians should provide validation, education, and resources especially support with sleep and cognitive therapy and/or pharmacotherapy can be recommended if insomnia persists. Regarding postpartum depression, the first-line treatment includes psychotherapy and antidepressants. For those with mild to moderate depression or hesitant to start on medications, psychosocial and psychotherapy alone should be sufficient. However, for those with moderate to severe symptoms, a combination of therapy and antidepressants, such as selective serotonin reuptake inhibitors, is recommended. Once an effective dose is reached, patients should be treated for an additional 6 to 12 months to prevent relapse. In severe cases, patients may need to be hospitalized to treat their symptoms and prevent complications such as self-harm or infanticide.Most SSRIs can be detected in breast milk, but only 10 percent of the maternal level. Thus, they are considered safe during breastfeeding of healthy, full-term infants. So, you mentioned SSRIs, but also SNRIs, bupropion, and mirtazapine are reasonable options for treatment. In patients who have never been treated with antidepressants, zuranolone (a neuroactive steroid) is recommended. Zuranolone is easy to take, works fast, and is well tolerated. Treatment with zuranolone is consistent with practice guidelines from the American College of Obstetricians and Gynecologists.While there are no current guidelines to manage postpartum psychosis, immediate hospitalization is necessary in severe cases. Patients can be started on mood stabilizers such as lithium, valproate, and lamotrigine, and atypical antipsychotics such as quetiapine, and olanzapine, to name a few. Medications like lithium can be eliminated through breast milk and can expose infants to toxicity.The use of medications such as SSRIs, carbamazepine, valproate, and short-acting benzodiazepines are relatively safe and can be considered in those with plans to breastfeed. Ultimately, it is a decision that the patient can make after carefully discussing and weighing the pros and cons of the available medical management. While the prognosis of peripartum mood disorders is relatively good with many patients responding well to treatments, these disorders can have various negative consequences. Individuals with a history of postpartum blues are at increased risk of developing postpartum depression. Similarly, those with a history of postpartum psychosis are at risk of experiencing another episode of psychosis in future pregnancies. Additionally, postpartum depression can have a detrimental effect on mother-infant bonding and affect the growth and development of the infant. These children may have difficulties with social interactions, cognitive development, and depression. In summary, following the birth of a baby can pose new challenges and often is a stressful time for not only the mother but also other family members. Validation and reassurance from primary care physicians in an empathetic and understanding manner may offer support that many mothers may not have in their close social circle. As the first contact, primary care physicians can identify cues and offer support promptly that will not only improve the mental well-being of mothers but also that of the growing children.___________________________Conclusion: Now we conclude episode number 171, “Postpartum blues, depression, and psychosis.” These conditions may be more common than you think. So, be alert during your prenatal and postpartum visits and start management as needed. Psychotherapy and psychosocial therapy alone may be effective but do not hesitate to start antidepressants or antipsychotics when necessary. Make sure you involve the family and the patient in the decision-making process to implement an effective treatment.This week we thank Hector Arreaza and Vy Nguyen. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Raza, Sehar K. and Raza, Syed. Postpartum Psychosis. National Library of Medicine. Last updated Jun 26, 2023. https://www.ncbi.nlm.nih.gov/books/NBK544304/Balaram, Kripa and Marwaha, Raman. Postpartum Blues. National Library of Medicine. Last updated Mar 6, 2023. https://www.ncbi.nlm.nih.gov/books/NBK554546/Mughal, Saba, Azhar, Yusra, Siddiqui, Waquar. Postpartum Depression. National Library of Medicine. Last updated Oct 7, 2022. https://www.ncbi.nlm.nih.gov/books/NBK519070/Royalty-free music used for this episode: Good Vibes by Simon Pettersson, downloaded on July 20, 2023, from https://www.videvo.net/royalty-free-music/.

In this episode, we discuss the groundbreaking FDA approval of zuranolone, the first oral medication specifically targeting postpartum depression. Could zuranolone's novel mechanism of action as an allopregnanolone agonist herald a new era of rapid-onset, targeted treatments for this debilitating condition affecting 1 in 8 new mothers? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 54 Zuranolone for the Treatment of Postpartum Depression

Guest: Dr. Stephanie Waggel Perinatal Psychiatrist   In this episode: List two things that make a patient susceptible to PMADS (perinatal mood and anxiety disorders). Describe two treatment options for PMADS. Explain what makes the drug, Zuranolone, so effective for treating postpartum depression. This episode is eligible for CEUs. Visit https://handtohold.org/resources/podcasts/nicu-heroes/ to complete the questionnaire. It is the sole responsibility of the individual to verify if this credit is valid and eligible for use in your State and/or for your discipline for licensure or certification renewal.  

In this episode, we discuss performing Cesarean for fetal weights at lower thresholds than currently recommended. Then we discuss new literature regarding utility of pelvic exams or screening asymptomatic women and early rupture of membranes after cervical ripening with a Foley bulb. Then we discuss an editorial discussing selecting the best test and hysteroscopy for miscarriage after embryo transfer. Plus, a new RCT that examines stopping oxytocin once a patient is in active labor. Finally, we answer listener questions about harms of yearly pap smears and whether we plan to use Zuranolone for treatment of postpartum depression. Buckle up!00:01:00 Cesarean for Fetal Weight > 4000 g00:13:20 Pelvic Exams in Asymptomatic Women00:30:10 Early Amniotomy After Foley Bulbs 00:33:43 The Best Test: Hysteroscopy for Miscarriage00:40:59 Stopping Oxytocin in Active Labor00:45:00 Listener Question: Harms Of Yearly Paps00:55:26 Listener Question: ZuranoloneFollow us on Instagram @thinkingaboutobgyn.

We are back from parental leave: exhausted, but ready to put out more episodes for our amazing listeners. Here is our first episode back on zuranolone, an FDA approved mediation for peripartum depression.  Check out the website for the Rosh Review question of the week.  Twitter: @creogsovercoff1 Instagram: @creogsovercoffee Facebook: www.facebook.com/creogsovercoffee Website: www.creogsovercoffee.com Patreon: www.patreon.com/creogsovercoffee You can find the OBG Project at: www.obgproject.com

Join us as we review recent articles and news featured in The DIGEST #43 and #44, including bempedoic acid to lower cardiovascular risk, Alpha-Gal Syndrome, tick bites and meat allergy, orforglipron an oral GLP1 agonist for weight loss, zuranolone for postpartum depression, DOACs for VTE of malignancy, monoclonal antibodies (mAbs) for Dementia, cytisinicline for smoking cessation, and two kiwis a day for constipation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Paul Williams (@PaulNWilliamz), Nora Taranto (@norataranto), and Matt Watto (@doctorwatto). Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | Free CME! Credits Written and Hosted by: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewers: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Sponsor: Netsuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance for free, at NetSuite.com/CURBSIDERS Sponsor: Locumstory  Get a comprehensive view of locums and decide if it's right for you at locumstory.com. Sponsor: Grammarly  Go to grammarly.com/GO to download for FREE today. Sponsor: Pathway Download the Pathway app today by visiting pathway.md Show Segments Intro, disclaimer Bempedoic Acid for CV risk reduction DOACs to prevent recurrent VTE of malignancy Cytisinicline for smoking cessation Alpha-Gal Syndrome, tick bites, and meat allergy Zuranolone for postpartum depression Orforglipron, an oral GLP1 agonist, for weight management mAbs for Alzheimer's dementia Kiwis to prevent constipation Outro

In this episode of Mommy Brain Revisited I talk with Dr. Kristina M. Deligiannidis, MD, Professor, Institute of Behavioral Science, Feinstein Institutes for Medical Research, Director, Women's Behavioral Health, Zucker Hillside Hospital, Northwell Health, Professor, Psychiatry, Molecular Medicine and Obstetrics & Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, USA. We talk about her research on the development of neurosteroid treatments for postpartum depression. In particular we talk about her work on the new FDA approved oral medication for postpartum depression – Zuranolone as well as some practical information on Zuranolone, itself. Don't miss this episode on Mommy Brain Revisited. It's an important one for understanding the current treatment options and challenges for perinatal mental illness. For more information on Dr Deligiannidis' work and her contact information see: https://feinstein.northwell.edu/institutes-researchers/our-researchers/kristina-m-deligiannidis-md Download one of the publications that we talk about here: https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.20220785 --- Support this podcast: https://podcasters.spotify.com/pod/show/mommybrainrevisited/support

Thank you Christian Earl, OMS IV for developing this podcast. Thank you Erin Callahan, OMS IV and Westin Wong, OMS IV for participating in development of this topic. This podcast contains high yield shelf information about Major Depressive Disorder with Peripartum Onset at the beginning. The conversation from there describes some of the aspects of this type of depression and why it needs greater attention. The podcast then looks at Zuranolone directly with important information about the nuances of prescribing this molecule. We enjoyed our discussion and hope you do too! Thank you to the immortal Jordan Turner for creating the perfect bumper music!

On this week's Trending News EU episode, Jack and Ollie discuss a few recent EU-based newsworthy items including the potential for robotics to transform surgical and patient care (0.35), exciting progress being made in Europe to advance decentralised clinical trials (7.26), and much needed hope for those suffering with postpartum depression following approval in the US of an innovative new medicine (15.48). Podcast Tags: healthcare, healthcare news, robotics, AI, artificial intelligence, NHS, health equity, EU, clinical trials, neuroscience, depression, postpartum depression, major depressive disorder, biogen Source Links:  Outdated legacy tech risks driving frustrated staff out of the NHS Millions of hours of doctors' time lost each year to ‘inadequate' IT systems St Bartholomew's perform first robotic-assisted lung biopsy Is Outdated Technology Holding Back UK Surgeons? The robotics revolution has arrived, and it is changing how we do surgery €60 million committed to establish AI and robotics in healthcare Robotic surgery supporting faster recoveries and better outcomes Different, But Not Poles Apart: Running Decentralized Clinical Trials In EU & US Principles-Based vs Prescriptive: How US & EU Compare In Their Approach To Decentralized Trials How clinical trials benefit from decentralized solutions: A Nordic case study The trial of the future: using digital technologies to enable decentralized trials Decentralized trials getting some attention on the international regulatory front No place like home? Stepping up the decentralization of clinical trials A new pill in the U.S. offers hope to mothers with postpartum depression Postpartum psychosis: new mothers speak out over need for support Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program Impact of new pill to treat postpartum depression will depend on price Biogen, Sage's postpartum depression approval overshadowed by larger rejection For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC. Jen Burke, Director  Jen.Burke@vynamic.com Jack Young, Senior Director Jack.Young@vynamic.com Oliver May, Senior Manager  Oliver.May@vynamic.com  

As a true testament that we read each one of our Podcast Facebook messages, this is a “You asked, We answered” episode regarding 3 main recent topics: 1. dose of oral MI for PCOS, 2. Zoranalone for Major Depressive Disorder, and 3. the “shoulder shrug” maneuver for shoulder dystocia.

In this episode, Ayesha talked about the FDA approval of Zurzuvae (zuranolone) the first oral tablet for the treatment of postpartum depression (PPD). While the approval is a major win in PPD, as current treatments involve administration by infusion or use of general antidepressants, Zurzuvae developers Biogen and Sage Biotech were banking on getting approval for it in major depressive disorder (MDD). However, the FDA rejected it in MDD and only handed the approval in PPD. Hear more about the drug and the approval/rejection in this episode. Ayesha also talked about Johnson & Johnson's latest bankruptcy attempt related to its talc baby powder cases that was shot down by a US Bankruptcy Court. The company said it will appeal the decision as it continues to offer talc claimants a $8.9 billion settlement, which it says is the best way to resolve the cases in a timely and financially equitable manner. This is the company's second bankruptcy attempt, both of which have been turned down so far. Listen to the full episode to learn more about Johnson & Johnson's ongoing legal saga.Read the full articles here:Zurzuvae Earns Win for Postpartum Depression, Faces Challenges in MDDTalc Litigation Saga Continues: Court Rejects J&J's Latest Bankruptcy AttemptFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @XtalksInstagram: @XtalksFacebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

Zuranolone (Zurzuvae) is newly approved for postpartum depression, but does it work in regular depression? And why did they put so many “Zs” in the name?CME: Take the CME Post-Test for this EpisodePublished On: 08/14/2023Duration: 22 minutes, 54 secondsChris Aiken, MD has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

I'm excited that today's episode covers the new postpartum depression medication, Zuranalone (brand name Zurzuvae). This is the first pill for PPD and was just recently approved by the FDA. It differs from the IV infusion Braxanalone, which was FDA approved in 2019. As with any new medication, there are many questions to consider if we are to stay ahead of any misinformation and hesitations. Join us to learn what you need to know and understand about this fantastic new tool in the treatment of PPD.  Dr. Samantha Meltzer-Brody is the Assad Meymandi Distinguished Professor and Chair of the Department of Psychiatry at the University of North Carolina at Chapel Hill. She is an internationally recognized reproductive psychiatrist and clinician-scientist who also directs the UNC Center for Women's Mood Disorders. Her work has focused on developing a comprehensive integrated clinical and research project in women's mood disorders across the reproductive life cycle. Dr. Meltzer-Brody investigates the epidemiologic and biological predictors of perinatal biomarkers, as well as the impact of adverse life events.  Show Highlights: An explanation for the layperson about Zuranolone—and why this is an exciting breakthrough in pill form How SSRIs (Selective Serotonin Reuptake Inhibitors) came to be used in the treatment of PPD, even though they have downsides and significant side effects Why the new drug is different than traditional antidepressants previously used to treat PPD What the clinical trials revealed about Zuranolone side effects, efficacy, and breastfeeding considerations When Zuranolone will be available The overall significance of this new medication Why postpartum is different from major depression–and should be treated differently Resources: Connect with Dr. Samantha Meltzer-Brody:   Visit www.postpartum.net for resources and support!  Visit www.postpartum.net/professionals/certificate-trainings/ for information on the grief course.   Visit my website, www.wellmindperinatal.com, for more information, resources, and courses you can take today! Learn more about your ad choices. Visit megaphone.fm/adchoices

Zuranolone is a new FDA approved medication for postpartum depression, a condition affecting 20% of postpartum women. In this episode, we'll cover the science behind the medication - the mechanism of how it works - the data and research that led to the approval, and four different aspects that require additional information and study to figure out who is going to be the ideal patient for this new and exciting treatment tool. To learn more about me and my reproductive & integrative psychiatry clinic helping patients across California, please visit - AnnaGlezerMD.comTo sign up for the Fellowship in Reproductive & Integrative Psychiatry, please visit: PsychiatryFellowship.comLinks:  AJP Zuranolone for PPD Article: https://pubmed.ncbi.nlm.nih.gov/37491938/ 

Thousands of new moms suffer from postpartum depression without effective treatment. But a new postpartum depression drug approved in the U.S. — Zuranolone — could offer some hope. Two clinical trials found it effective and fast-acting. Guest host Anthony Germain speaks with a mom who participated in one of the trials and that trial's principal investigator; and discusses the interest the drug is getting on our side of the border with Dr. Tuong Vi Nguyen, a reproductive psychiatrist at the McGill University Health Centre.

In 2019, brexanolone, better known as Zulresso, became the first postpartum depression (PPD) drug to receive FDA approval. While we have previously discussed this IV medication for PPD in other episodes, there is now a novel oral version of this antidepressant which has made the news as of last week (ie, early august 2023). That medication was known as SAGE 217 during the clinical trials, but it is now known as zuranolone (ZURZUVAE™). YEP.. in the first week of August 2023, the US Food and Drug Administration approved the medication zuranolone for the treatment of postpartum depression – making it the first FDA-approved oral pill in the United States specifically for postpartum depression. Do you know how this medication works? What's the data on it? Does ACOG have an opinion on this? And what's the special FDA warning that ended up as a BLACK BOX on the approval? In this episode, we will learn the ins and outs of Zurzuvae.

The FDA approved the first pill for postpartum depression on Friday. The drug is called zuranolone, and unlike other antidepressants, it's specifically designated for postpartum depression, a condition that affects around 1 in 7 new mothers. The big picture: Zuranolone is taken daily for two weeks. Clinical trials showed that the drug could ease depression in as little as three days. Plus, young workers are redefining the American dream. And, Spanglish is making a comeback. Guests: Axios' Felix Salmon, Arielle Dreher and Marina Franco. Credits: Axios Today is produced by Erica Pandey, Alexandra Botti, Fonda Mwangi, Robin Linn and Alex Sugiura. Music is composed by Evan Viola. You can reach us at podcasts@axios.com. You can text questions, comments and story ideas to Niala as a text or voice memo to 202-918-4893. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today's Headlines: The DOJ requested a protective order after Trump's provocative social media post. Judge Tanya Chutkan set a deadline for response which Trump's team sought to extend. Despite their efforts, Chutkan adhered to the original deadline. Supreme Court Justice Clarence Thomas's ownership of a lavish RV came to light. The vehicle, costing $267,000, was partially financed by Anthony Welters, raising questions about transparency. Florida's education scene saw a reversal after Governor Ron DeSantis tried to remove AP Psychology from the curriculum. Now, students can take the course in full. DeSantis is also pushing for a "classical learning test" alternative to the SAT and ACT. The FDA approved Zuranolone, a rapid-acting pill for postpartum depression, though its pricing is pending DEA review. Additionally, the CDC recommends an RSV shot for infants under 8 months to reduce hospitalizations.  Resources/Articles mentioned in this episode: AP News: Prosecutors ask judge to issue protective order after Trump post appearing to promise revenge  NY Times: Clarence Thomas's $267,230 R.V. and the Friend Who Financed It  NPR: AP psychology class may be available to Florida students after all  Axios: Florida eyes "classical" education agenda  NY Times: For the First Time, There's a Pill for Postpartum Depression  NPR: RSV prevention shot for babies gets OK from CDC  Morning Announcements is produced by Sami Sage alongside Amanda Duberman and Bridget Schwartz Edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

A pill that is being developed to treat postpartum depression is showing promise for new mothers. This according to newly released clinical trial data published in The American Journal of Psychiatry. Here's what you should know about Zuranolone...

Dr. Kristina Deligiannidis, Perinatal Psychiatrist, joins Lisa Dent to discuss her findings within a study surrounding the postpartum depression pill Zuranolone. Listen in while Dr. Deligiannidis breaks down her findings as Principal Investigator on the study and what the data means. Follow The Lisa Dent Show on Twitter:Follow @LisaDentSpeaksFollow @SteveBertrand Follow @kpowell720 Follow @maryvandeveldeFollow @LaurenLapka

Drs Madhukar H. Trivedi and Christoph U. Correll discuss the predictors of suicidal ideation, attempt, and death as well as how to address the topic of suicidality with patients and their loved ones. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984464). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Depression https://emedicine.medscape.com/article/286759-overview Prevalence of Suicidality in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Comparative Studies https://pubmed.ncbi.nlm.nih.gov/34603096/ Twelve-Month Prevalence of and Risk Factors for Suicide Attempts in the World Health Organization World Mental Health Surveys https://pubmed.ncbi.nlm.nih.gov/20816034/ Persistent Depressive Disorder https://www.ncbi.nlm.nih.gov/books/NBK541052/ Risk and Protective Factors for Suicide and Suicidal Behavior https://www.div12.org/wp-content/uploads/2012/10/Suicide-Risk-Factors-with-Graphics-Div12.pdf Prevention of Suicide by Clozapine in Mental Disorders: Systematic Review https://pubmed.ncbi.nlm.nih.gov/36640481/ Lithium Suicide Prevention: A Brief Review and Reminder https://pubmed.ncbi.nlm.nih.gov/30834169/ Trauma-Focused Psychotherapies for Post-Traumatic Stress Disorder: A Systematic Review and Network Meta-analysis https://pubmed.ncbi.nlm.nih.gov/34473342/ Intranasal Esketamine and Current Suicidal Ideation With Intent in Major Depression Disorder: Beat the Clock, Save a Life, Start a Strategy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203410/ Dextromethorphan/Bupropion (Rx) https://reference.medscape.com/drug/auvelity-dextromethorphan-bupropion-4000211 Status Update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014 https://pubmed.ncbi.nlm.nih.gov/25520892/ Psychometric Properties of the Beck Depression Inventory-II: A Comprehensive Review https://pubmed.ncbi.nlm.nih.gov/24402217/ The 9-Item Concise Health Risk Tracking – Self-Report (CHRT-SR9) Measure of Suicidal Risk: Performance in Adult Primary Care Patients https://pubmed.ncbi.nlm.nih.gov/36865066/ Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR(*)D Measurement-Based Care https://pubmed.ncbi.nlm.nih.gov/17406651/ Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR): Results From the STRIDE (CTN-0037) Study https://pubmed.ncbi.nlm.nih.gov/29325238/ Mechanisms of Action and Clinical Efficacy of NMDA Receptor Modulators in Mood Disorders https://pubmed.ncbi.nlm.nih.gov/28711661/ Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics https://pubmed.ncbi.nlm.nih.gov/30262987/ Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/36811520/ GABA Receptor Positive Allosteric Modulators https://www.ncbi.nlm.nih.gov/books/NBK554443/# Conjoint Therapy https://dictionary.apa.org/conjoint-therapy

This week on Pharm5: Adult Immunization Schedule 2023 Pediatric Immunization Schedule 2023 Rapid acting antidepressant, Zuranolone 2022 NAPLEX/MPJE Pass Rates State of the Union Address Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Murthy N, Wodi AP, Cineas S, Ault KA. Recommended Adult Immunization Schedule, United States, 2023. https://doi.org/10.7326/M23-0041. Ann Int Med. 2023. The 5 biggest changes in the 2023 adult vaccine schedules. Medscape. http://bit.ly/40WmmX5. Published February 9, 2023. Accessed February 9, 2023. Committee on Infectious Diseases. Recommended Childhood and Adolescent Immunization Schedule: United States, 2023. https://doi.org/10.1542/peds.2022-061029. Pediatrics. 2023. Swift D. AAP approves 2023 Child and adolescent immunization schedule. Medscape. http://bit.ly/3RMFhPD. Published February 9, 2023. Accessed February 9, 2023. Biogen and Sage Therapeutics announce FDA accepts filing of New Drug Application and grants priority review of Zuranolone in the treatment of major depressive disorder and postpartum depression. Biogen. http://bit.ly/3HR6pbB. Accessed February 9, 2023. Data & Research. National Association of Boards of Pharmacy. http://bit.ly/40W5qQv. Accessed February 9, 2023. Aislinn Antrim E. State of the union address focuses on affordable health care, cost of insulin. Pharmacy Times. http://bit.ly/3jPc4qT. Published February 8, 2023. Accessed February 9, 2023. Full 2023 President Biden State of the Union Annotated and fact checked. CNN. http://bit.ly/3YlJs7w. Accessed February 9, 2023.

Type 2 diabetes treatment discontinued; Depression, postpartum treatment gets Priority Review; Hypothyroid treatment recalled; FDA warns about weight loss supplement; First retinopathy of prematurity treatment for preterm infants approved.

On this week's Tech Nation, it's about developing medicines which enable the body to heal itself. First up, treating depression in a whole new way … and rapidly. Dr. Jeff Jonas, the Chief Innovation Officer and Director of Sage Therapeutics, talks about their drug Zuranolone, nearing the end of its drug approval journey. Then, Craig Parker, the CEO of Surrozen, talks about their work with the W-N-T pathway, or Wnt pathway. Their initial candidate for treatment? Repairing the liver.

Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depression treatment.

Should zuranolone be a first-line treatment for postpartum depression? In this episode, Dr. Phelps discusses a randomized trial of zuranolone—a new neuromodulatory steroid—in the context of previous guidelines for the treatment of postpartum depression.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about Premium Membership here Earn 0.5 CMEs: Quick Take Vol. 35 Effect of Zuranolone vs Placebo in Postpartum Depression  

Zuranolone is a neurosteroid that is inching its way toward FDA approval in depression. In some ways it's similar to brexanolone (Zulresso) – the IV therapy approved in 2019 for postpartum depression – and in other ways it's different.CME: Take the CME Post-Test for this episodePublished On: 04/04/2022Duration: 12 minutes, 20 secondsRelated Articles: “Brexanolone: A New Treatment for Postpartum Depression,” The Carlat Psychiatry Podcast, August 2019“Brexanolone (Zulresso) for Postpartum Depression,” The Carlat Psychiatry Report, June 2019“Brexanolone: A New Treatment for Postpartum Depression,” The Carlat Psychiatry Report, January 2019Chris Aiken, MD, Kellie Newsome, PMHNP, and Margaret Chisolm, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

https://astralcodexten.substack.com/p/highlights-from-the-comments-on-zulresso Thanks to everyone who commented on Zounds! It's Zulresso and Zuranolone and on the followup Progesterone Megadoses Might Be A Cheap Zulresso Substitute. I'm constantly impressed by the expertise of commenters here and on how much better the biomedical comment threads are compared to some of the others. Among the things I learned: — Metacelsus (who writes the blog De Novo) doubts the price estimates I posted: There's no way it costs $10,000 to $20,000 a gram at scale. Those 3 chemical supply companies specialize in having a very large catalog of small quantities of chemicals for biologists to test in their experiments. (I have personally ordered from 2 out of those 3 for my research.) The price they charge per gram is not competitive at all. He also wrote a longer blog post about the science of progesterone here. — Douglas (who writes the blog A Mindful Monkey) clears up some mechanism details I missed: From Stahl's: 'the precipitous decline in circulating and presumably brain levels of allopregnanolone hypothetically trigger the onset of a major depressive episode in vulnerable women. Rapidly restoring neurosteroid levels over a 60-hour period rapidly reverses the depression, and the 60 hour period seems to provide the time necessary for postpartum patients to accommodate their lower levels'. So the idea is the taper of the steroid is a helpful part.

https://astralcodexten.substack.com/p/zounds-its-zulresso-and-zuranolone How excited should we be about the latest class of antidepressants? 1: What is Zulresso? Wikipedia describes Zulresso as “A bat-winged, armless toad with tentacles instead of a face... ” - no! sorry! That's Zvilpogghua, one of the Great Old Ones from the Lovecraft mythos. Zulresso is the brand name of allopregnanolone (aka brexanolone), a new medication for post-partum depression. It's interesting as a potential missing link between hormones and normal mood regulation. 2: What do you mean by “missing link between hormones and normal mood regulation?” Allopregnanolone is a naturally-occuring metabolite of the female hormone progesterone. In 1981, scientists found it was present in unusually high concentrations in the brain (including male brains), suggesting that maybe the brain was making it separately and using it for something. They did some tests and found that it was a positive allosteric modulator of GABA.  

On this week's Tech Nation, it's about developing medicines which enable the body to heal itself. First up, treating depression in a whole new way … and rapidly. Dr. Jeff Jonas, the Chief Innovation Officer and Director of Sage Therapeutics, talks about their drug Zuranolone, nearing the end of its drug approval journey. Then, Craig Parker, the CEO of Surrozen, talks about their work with the W-N-T pathway, or Wnt pathway. Their initial candidate for treatment? Repairing the liver.

On this week's Tech Nation, it's about developing medicines which enable the body to heal itself. First up, treating depression in a whole new way … and rapidly. Dr. Jeff Jonas, the Chief Innovation Officer and Director of Sage Therapeutics, talks about their drug Zuranolone, nearing the end of its drug approval journey. Then, Craig Parker, the CEO of Surrozen, talks about their work with the W-N-T pathway, or Wnt pathway. Their initial candidate for treatment? Repairing the liver.

FirstWord Pharma PLUS editors Becky Simon, Michael Flanagan and Simon King discuss Eli Lilly's decision to file its investigational Alzheimer's disease treatment donanemab for accelerated approval with the FDA, take a closer look at Intellia Therapeutics' pivot into CAR-T, question whether momentum is building for Big Pharma in-licensing deals and break down expert feedback on Sage Therapeutics depression drug zuranolone.

This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax's vaccine for COVID and a novel treatment for MDD show promise. Also the FDA issue warning concerning hand sanitizers.